CGP-53716 is primarily used in research settings to study cellular signaling pathways, particularly those involving protein kinases. It acts as a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase, making it a valuable tool for investigating the role of PDGFR in various biological processes, including cell proliferation, migration, and differentiation. Researchers utilize this compound to explore its potential in understanding diseases such as cancer, fibrosis, and atherosclerosis, where PDGFR signaling is often dysregulated. Additionally, CGP-53716 is employed in preclinical studies to evaluate its efficacy as a therapeutic agent, particularly in targeting PDGFR-driven malignancies. Its specificity and potency make it a key compound in the development of targeted kinase inhibitors for clinical applications.